Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Intravitreal Anti-VEGF

  • Home
  • Intravitreal Anti-VEGF
Disparities in Access to Intravitreal Anti-VEGF Therapies Among Medicare Advantage Versus Fee-for-Service Beneficiaries
Posted innews Ophthalmology

Disparities in Access to Intravitreal Anti-VEGF Therapies Among Medicare Advantage Versus Fee-for-Service Beneficiaries

Posted by MedXY By MedXY 07/05/2026
Medicare Advantage beneficiaries receive fewer higher-cost anti-VEGF injections compared to Fee-for-Service patients, highlighting potential access disparities to newer ophthalmic therapies.
Read More
  • Comparing Early Restrictive and Liberal Fluid Strategies in Sepsis-Induced Hypotension: Long-Term Effects on Patient-Centered Outcomes
  • Corneal Nerve Alterations and Sensory Deficits in Unilateral Noninfectious Anterior Uveitis: A Cross-Sectional Study
  • Enhancing Glaucoma Diagnosis in Myopia: Validating OCT-Based Prespecified Rules for Optic Neuropathy Detection
  • Disparities in Access to Intravitreal Anti-VEGF Therapies Among Medicare Advantage Versus Fee-for-Service Beneficiaries
  • Elevated Blood Manganese Linked to Increased Risk of Head and Neck Squamous Cell Carcinomas: Insights from Mendelian Randomization
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in